OBJECTIVE: Glycaemic control is critical to prevent diabetic complications and mortality. This 6-month, open-label, observational study assessed the efficacy and safety of switching Japanese patients with type 2 diabetes from neutral protamine Hagedorn (NPH) insulin to insulin detemir. METHODS: Patients with type 2 diabetes (n = 126) receiving basal-bolus insulin therapy with NPH insulin plus rapid-acting insulin analogues were recruited. NPH insulin was replaced with insulin detemir for 6 months. Glycosylated haemoglobin (HbA 1c ), fasting plasma glucose (FPG), daily glucose levels and hypoglycaemia were monitored.
Introduction
Maintenance of good glycaemic control in diabetes is critical for the prevention of diabetic complications and death, 1 -3 and many patients with type 2 diabetes mellitus require basal-bolus insulin therapy to achieve acceptable blood glucose levels. Long-acting insulin analogues, such as insulin detemir, have been shown to be well tolerated and effective as the basal insulin in intensive insulin therapeutic regimens. 4 Several multicentre trials have demonstrated that the use of insulin detemir as the basal component of a basal-bolus insulin regimen provides more predictable glycaemic control with less day-to-day variation, lower fasting plasma glucose (FPG) and fewer hypoglycaemic episodes (especially at night) than neutral protamine Hagedorn (NPH) insulin. 5 -7 The beneficial effects of insulin detemir have been confirmed in a Japanese phase III clinical trial. 8 These findings were, however, limited by the study design, since the insulin detemir was injected using the same dosing schedule (i.e. frequency and time of day) as the NPH insulin it replaced, with a starting dose equivalent to 70% of the NPH insulin. The optimum regimen for insulin detemir in routine clinical practice in Japan remains unknown.
The Japan Diabetes Clinical Data Management Study Group (JDDM) was established to promote diabetes clinical research in Japan. 9 Data on patients at healthcare institutes across Japan are collected in the Computerized Diabetes Care (CoDiC ® ) database, an information system developed by JDDM to amass data on the management of diabetes in daily practice. 9 This database was used to devise a multicentre open-label trial to investigate the efficacy and safety of switching from NPH insulin to insulin detemir in patients with type 2 diabetes who were previously on basalbolus therapeutic regimen with NPH insulin plus rapid-acting insulin analogues. Changes in insulin dose in the insulin detemir regimen and effects on patients' nocturnal quality of life were also monitored during the 6-month observation period of the study.
Patients and methods

STUDY POPULATION
The study participants were recruited sequentially, between January and December 2008, from patients with type 2 diabetes attending the outpatient clinics in 32 JDDMaffiliated centres for routine treatment. Inclusion criteria were: (i) age ≥ 20 years; (ii) treatment with basal-bolus insulin regimen (NPH insulin plus rapid-acting insulin analogues) for ≥ 12 weeks without changing any oral hypoglycaemic agents; (iii) glycosylated haemoglobin (HbA 1c ) ≥ 7.5 -< 11.0%; and (iv) willingness to conduct and report self-monitoring of blood glucose at home. Patients with proliferative retinopathy, recent macrovascular events, unawareness of hypoglycaemia, or episodes of repeated severe hypoglycaemia were excluded, as were pregnant women. Demographic, clinical and laboratory parameters were recorded for each patient.
The study was designed in accordance with the Guidelines for Epidemiological Studies in Japan. 10 The study received ethical approval from the Ethics Committee of the JDDM, which comprised external members of the public, including patients with diabetes, lawyers and experts in ethical matters. Written informed consent was obtained from all patients enrolled in the study. Insulin detemir in type 2 diabetes detemir, while the bolus rapid-acting insulin analogue remained unchanged. For patients previously on once-daily NPH insulin (at dinner time or bedtime), the starting dose of insulin detemir was identical to that of their previous NPH insulin. For patients previously on twice-daily NPH insulin, insulin detemir was administered once daily at 70% of the total dose of their previous NPH insulin. The basal dose of insulin detemir was titrated in all patients to reach a target FPG of < 110 mg/dl, and was followed by titration of the bolus insulin.
The prior oral hypoglycaemic agents were continued during the observation period, although participating physicians were free to decrease or stop (but not increase) treatment as necessary. The use of other insulin preparations was disallowed.
SELF-MONITORING OF GLUCOSE AT HOME
Patients continued to self-monitor their glucose levels as per their normal method. All patients were directed to monitor FPG before breakfast at least three times per week for the duration of the study. Patients were also requested to monitor their daytime glucose profile just before the start of the study (baseline) and at 6 months after switching to insulin detemir. The most recent glucose measurement taken at home before entering the study was used as the baseline value.
ASSESSMENT OF ENDPOINTS
Body weight, blood pressure and the dose of insulin were recorded at each clinic visit (approximately every month). HbA 1c (Japan Diabetes Society units) was assessed every month by high performance liquid chromatography.
QUALITY OF LIFE
The quality of life of all patients was assessed by the insulin therapy related quality of life at night (ITR-QOLN) questionnaire, 11 -13 at the start of the study (baseline) and at the end of the 6-month observation period. The ITR-QOLN was designed and validated to measure the impact of insulin therapy on quality of life, focusing on the period from bedtime to early morning. The questionnaire included 21 questions divided into four domains: anxiety before sleep; disturbances during sleep; glycaemic control before breakfast; and well-being.
HYPOGLYCAEMIA AND SEVERE HYPOGLYCAEMIA
Hypoglycaemia was defined as selfmonitored blood glucose < 55 mg/dl. Severe hypoglycaemia was defined as the inability of patients to treat themselves without assistance.
STATISTICAL ANALYSES
Statistical analyses were conducted using SPSS ® statistical software, version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Data were presented as mean ± SD. Changes from baseline in HbA 1c , FPG, body weight and the dose of insulin detemir were analysed by Dunnett's test under an analysis of variance model, using 'visit' as fixed effect and 'subject' as random effect. The daytime glucose profile was assessed by Mann-Whitney U-test. ITR-QOLN data were analysed using the paired sample t-test. A Pvalue < 0.05 was considered to be statistically significant.
Results
The study enrolled 153 patients who met the inclusion criteria, agreed to participate in the study and were registered on the database, and 126 (82%) completed the study. In total, 27 (18%) patients withdrew: 16 (10%) failed to self-monitor their glucose levels; five (3%) M Oishi, N Abe, H Yokoyama et al. Insulin detemir in type 2 diabetes were lost to follow-up; and six (4%) discontinued for other reasons. The baseline demographic characteristics of the 126 patients who completed the study are given in Table 1 .
Changes in mean HbA 1c and FPG over time are shown in Fig. 1A and 1B . The mean HbA 1c decreased significantly from 4 months (P < 0.05) after switching to insulin detemir and was significantly lower than baseline values at 6 months (7.88 ± 0.99% vs 8.14 ± 0.92%, P < 0.001; Fig. 1A ). There was a significant decrease in mean FPG compared with baseline from month 1 through 6 after switching to insulin detemir; the mean FPG level was significantly lower at 6 months than at baseline (150.8 ± 34.8 mg/dl vs 166.8 ± 38.9 mg/dl, P < 0.001; Fig. 1B ). The daytime glucose profile at baseline and at 6 months is shown in Fig. 1C . After switching to insulin detemir, plasma glucose was lower at all measured points during the day than baseline values, although this difference was statistically significant only at the point before breakfast (P < 0.01; Fig. 1C ).
There was a slight but significant decrease in body weight at 6 months compared with baseline (66.4 ± 12.8 kg vs 67.0 ± 12.8 kg, P < 0.001; Fig. 2 ). The total daily dose of insulin increased significantly from 42.6 ± 19.4 U at baseline to 45.8 ± 21.7 U at 6 months (P < 0.001); and the dose of basal insulin detemir increased significantly from 14.8 ± 8.4 U at baseline to 18.2 ± 10.9 U at 6 months (P < 0.001) (Fig. 3) . The increase in total dose of insulin was accounted for by the increase of basal insulin detemir.
The study included three patients who had previously received twice-daily NPH insulin. These patients were able to manage their blood glucose levels with a once-daily insulin detemir injection. The HbA 1c of these patients was 7.47 ± 0.59% at baseline and 7.50 ± 1.11% at 6 months. The total daily insulin doses in these three patients increased from 52.0 ± 30.8 U at baseline to 56.7 ± 32.3 U at 6 months (difference not statistically significant).
Twice-daily insulin detemir injection was required for nine (7%) patients. The total dose of bolus insulin of these patients increased from 15.1 ± 7.6 U while on NPH insulin to 32.1 ± 19.9 U following the switch to insulin detemir, resulting in a slight decrease of HbA 1c from 8.37 ± 0.96% at baseline to 8.33 ± 0.69% at 6 months; these differences were not statistically significant. These individuals were obese (BMI 29.1 ± 6.8 kg/m 2 ) and the total dose of insulin was 50.4 ± 26.1 U. Severe hypoglycaemia occurred in one of the 126 patients (0.8%) at 1 month after switching to insulin detemir and in one other patient within the 12-week period before switching from NPH insulin to insulin detemir. The former individual was able to complete the study. Data from self-monitoring of blood glucose levels revealed that 36 of 126 patients (29%) experienced minor hypoglycaemia.
Results of the ITR-QOLN questionnaire are shown in Fig. 4 . At 6 months, the total and well-being scores were significantly higher compared with those at baseline (P < 0.05 Total insulin Insulin detemir in type 2 diabetes and < 0.01, respectively). There were no significant differences in scores of other aspects of the questionnaire.
Discussion
The present study found that switching from NPH insulin to insulin detemir improved glycaemic control without increasing severe hypoglycaemia or weight gain in Japanese patients with type 2 diabetes who were already receiving basal-bolus insulin therapy. Strict glycaemic control has been shown to increase the risk of severe hypoglycaemia, 1 -3 but only one episode of severe hypoglycaemia was observed after switching to insulin detemir in the present study. It was not possible to determine the effect of insulin detemir on the overall risk of hypoglycaemia as not all patients provided sufficient self-monitored blood glucose data from the prestudy period. Data from the ITR-QOLN questionnaire suggested that patients experienced improvements in overall nocturnal quality of life, as well as wellbeing, after switching to insulin detemir.
The improvements in glycaemic control observed in the present study may be due to the pharmacokinetic profile of insulin detemir, which has a slower and milder peak and longer duration of effect than NPH insulin. 14 The total daily dose of insulin increased by approximately 4 U from baseline in the present study, starting from 1 month after switching to insulin detemir, and almost all of this increase could be accounted for by an increase in basal insulin detemir. This increase was accompanied by a simultaneous improvement in HbA 1c , suggesting that the increased basal insulin detemir contributed to the improvement of glycaemic control. These findings suggest that titration of the dose of insulin detemir on the basis of FPG in this study was effective.
Some physicians have suggested that insulin detemir (as basal insulin) should be administered twice daily because of its relatively short duration of action (< 24 h) in some patients. 15 Others have reported that once-and twice-daily injection are equally useful in patients with type 1 and type 2 diabetes. 16, 17 In the present study, nine patients (7%) required twice-daily injections of insulin detemir. These individuals were obese and needed very high doses of insulin because of marked insulin resistance. Thus, twice-daily insulin detemir may be required for some insulin resistant patients with type 2 diabetes.
Studies have found that switching to insulin detemir was associated with significant weight loss. 5,18 -21 Body weight decreased significantly, albeit modestly, from baseline to the end of the 6-month observation period in the present study. As weight gain is a common negative consequence of treatment with insulin 22, 23 and sulphonylurea, 24 the weight sparing effect of insulin detemir is considered highly beneficial. In a randomized crossover study, it was found that the weight sparing effect of insulin detemir was due to reduced food intake rather than increased energy expenditure, possibly through direct or indirect effects of insulin detemir on the hormones that control satiety. 25 This concept is supported by the finding that insulin detemir activates the hypothalamus, 26 which centrally controls appetite and body weight. 27 There were certain limitations to the present study, including the small sample size and observational study design. Additionally, the study did not include a control group and patients were not randomized. Data regarding some safety and efficacy parameters were provided by the patients themselves. Considering that the patients included in this study were treated at hospital clinics, specialist centres and family practices representative of the medical care facilities available in Japan, we believe that the study outcomes reflect reallife clinical practice in Japan. Finally, although the mean changes in some of the outcomes (e.g. HbA 1c , FPG and weight) were relatively small and the clinical relevance of these changes is unclear, it is important to consider that some patients achieved improvements in HbA 1c and other outcomes that were greater than the mean change. Thus, some, although not all, patients can clearly benefit from switching from NPH insulin to insulin detemir.
